Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias

Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.

PURPOSE Dasatinib is a dual Src/Abl inhibitor recently approved for Bcr-Abl+ leukemias with resistance or intolerance to prior therapy. Because Src kinases contribute to multiple blood cell functions by triggering a variety of signaling pathways, we hypothesized that their molecular targeting might lead to growth inhibition in acute myeloid leukemia (AML). EXPERIMENTAL DESIGN We studied growt...

Classification of acute myeloid leukemias

Therapy-Related Acute Myeloid Leukemias

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐ plasms occurring as an overwhelming complication in patients receiving previous cytotoxic chemotherapy and/or radiation therapy used to treat haematopoietic or solid malignancies or associated with immunosuppressive treatment for non-neoplastic rheumatologic/autoim‐ mune diseases or solid organ transplantati...

G-csf and Myeloid Leukemias

Various cytokines play roles in the process of granulocytic proliferation, differentiation and maturation from hemopoietic stem/progenitor cells and in the functional activation of mature granulocytes. Among these cytokines, the most essential is granulocyte colony-stimulating factor (G-CSF), which is a 19KD glycoprotein composed of 174 amino acids with one o-linked sugar chain. This molecule i...

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations. We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemi...